Jupiter Neurosciences Inc(US:JUNS) Globenewswire·2025-07-23 12:00Core Insights - Jupiter Neurosciences, Inc. is advancing its proprietary resveratrol-based platform, JOTROL, which offers significant advantages over traditional resveratrol formulations [1][3][10] - JOTROL has demonstrated a nine-fold increase in bioavailability compared to conventional resveratrol, while avoiding gastrointestinal side effects [3][7][10] - The company is progressing JOTROL towards a Phase IIa trial for Parkinson's Disease, supported by promising preclinical data [4][8][10] Scientific and Clinical Advantages - Resveratrol is known for its antioxidant, mitochondrial, and anti-inflammatory properties, but its therapeutic use has been limited due to poor bioavailability and GI side effects [2][9] - JOTROL promotes mitochondrial biogenesis and reduces neuroinflammation, addressing key factors in neurodegenerative diseases and aging [5][6] Product Development and Market Strategy - JOTROL is not only aimed at pharmaceutical applications but also serves as the foundation for the Nugevia consumer product line, targeting cognitive health, mitochondrial energy, and skin vitality [4][11] - The Nugevia product line is set to launch in Q3 2025, leveraging the same delivery technology as JOTROL to provide clinical-grade bioavailability in the wellness market [11] Intellectual Property and Market Potential - The company has secured intellectual property rights for JOTROL in major markets including the U.S., EU, China, Japan, and Hong Kong, valid through 2036 [7] - JOTROL's ability to cross the blood-brain barrier positions it as a potential treatment for CNS disorders such as Parkinson's and Alzheimer's [7][8]